---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-011132"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:31:11.865113+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M

## Summary
- GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.
- Total revenue $45.7M vs $98.2M; product revenue $40.7M (down 11% YoY); royalty revenue $5.0M.
- Non-GAAP adjusted net loss $0.3M ($0.01 per share) vs adjusted net income $22.4M ($0.56) a year ago.
- Cash and marketable securities $73.9M at March 31, 2022, down from $82.1M at Dec 31, 2021.
- Upcoming milestones for neratinib trials: SUMMIT Phase II data in HER2-mutated breast cancer and biliary tract cancer H1 2022.

## SEC filing metadata
- accession: 0001437749-22-011132
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/0001437749-22-011132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922011132/pbyi20220504_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-011132
- JSON: https://secwatch.observer/filing/0001437749-22-011132.json
- Plain text: https://secwatch.observer/filing/0001437749-22-011132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.